Fosamax vs Evenity (Romosozumab): Head-to-Head Efficacy Compared

How These Two Drugs Work Differently

Alendronate and romosozumab attack osteoporosis through opposite biological mechanisms, which explains their different efficacy profiles. Alendronate inhibits osteoclast-mediated bone resorption, slowing the rate at which bone breaks down. Romosozumab blocks sclerostin, a protein that suppresses bone formation, producing rapid new bone growth while simultaneously reducing resorption [1].

This distinction matters clinically. Bisphosphonates like alendronate preserve existing bone architecture. They do not rebuild bone that has already been lost. Romosozumab, by contrast, triggers a so-called "anabolic window" during its 12-month treatment course, during which bone mineral density (BMD) climbs steeply at rates not achievable with antiresorptive agents alone [2].

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis noted: "Anabolic therapy should be considered as initial therapy in patients at very high fracture risk" [3]. This recommendation reflected the growing recognition that, for patients with severe disease or recent fractures, starting with an agent that actively builds bone may confer advantages over beginning with resorption inhibition alone.

Alendronate binds tightly to hydroxyapatite in bone mineral, giving it a long skeletal half-life of roughly 10 years [4]. Romosozumab is a humanized monoclonal antibody administered as two subcutaneous injections once monthly for 12 doses. Its effects begin to wane within months of discontinuation if no follow-on antiresorptive therapy is given [2].

The ARCH Trial: Direct Head-to-Head Evidence

The ARCH trial (Active-contRolled FraCture Study in Postmenopausal Women with Osteoporosis at High Risk) remains the only large randomized controlled trial directly comparing romosozumab to alendronate. Published in the New England Journal of Medicine in 2017, it enrolled 4,093 postmenopausal women with osteoporosis and a prior fragility fracture [5].

Participants received either romosozumab 210 mg monthly or alendronate 70 mg weekly for the first 12 months. Both groups then transitioned to open-label alendronate for an additional 12 months. The primary endpoints were new vertebral fractures at 24 months and clinical fractures at the time of the primary analysis.

The results were definitive. At 24 months, romosozumab-to-alendronate reduced new vertebral fractures by 48% compared to alendronate alone (6.2% vs 11.9%, P<0.001) [5]. Clinical fractures fell by 27% (9.7% vs 13.0%, P<0.001), and nonvertebral fractures dropped by 19% (8.7% vs 10.6%, P=0.04) [5]. Hip fracture risk was 38% lower in the romosozumab group, though this finding did not reach statistical significance in the prespecified analysis [5].

BMD changes at 12 months told an equally striking story. Lumbar spine BMD rose 13.7% with romosozumab versus 5.0% with alendronate. Total hip BMD increased 6.2% with romosozumab versus 2.8% with alendronate [5]. These differences persisted through month 24 even after both groups had transitioned to alendronate.

Alendronate's Own Landmark Data: The FIT Trial

Before ARCH, alendronate's fracture-reduction evidence came primarily from the Fracture Intervention Trial (FIT), published in JAMA in 1998. FIT enrolled 6,459 postmenopausal women with low femoral neck BMD and followed them for a mean of 4.2 years [6].

In the vertebral fracture arm (FIT-1), which included women with existing vertebral fractures, alendronate 5-10 mg daily reduced the risk of new morphometric vertebral fractures by 47% over three years (RR 0.53 to 95% CI 0.41-0.68) [6]. Hip fractures fell by 51% in this high-risk subgroup (RR 0.49 to 95% CI 0.23-0.99) [6]. The clinical fracture arm (FIT-2), which enrolled women without prevalent vertebral fractures but with low BMD, showed a 44% reduction in vertebral fractures but no significant reduction in clinical fractures overall [7].

FIT established alendronate as a first-line osteoporosis therapy for over two decades. These numbers remain relevant because most patients today still begin treatment with a bisphosphonate, not an anabolic agent. Cost is the primary driver: generic alendronate costs roughly $20 to $50 per year, while romosozumab carries a list price near $22,500 annually [8].

Dr. Felicia Cosman, professor of medicine at Columbia University and a lead investigator on multiple osteoporosis trials, has stated: "The data clearly show romosozumab produces larger and faster BMD gains than any antiresorptive. But access, cost, and the cardiovascular signal all factor into real-world prescribing decisions" [9].

BMD Gains: Quantifying the Difference

Bone mineral density improvement is the most commonly tracked surrogate marker for fracture risk reduction. At every skeletal site measured, romosozumab outpaced alendronate during the first 12 months of therapy.

In ARCH, lumbar spine BMD gains with romosozumab were 13.7% at month 12, nearly triple the 5.0% seen with alendronate [5]. At the total hip, romosozumab produced a 6.2% increase compared to 2.8% with alendronate [5]. The femoral neck showed similar separation: 4.9% gain with romosozumab versus 1.7% with alendronate [5].

Data from the FRAME trial, which compared romosozumab to placebo in 7,180 postmenopausal women, confirmed these BMD dynamics. Romosozumab increased lumbar spine BMD by 13.3% at 12 months versus 0.0% with placebo [10]. After transition to denosumab in the second year, the romosozumab group maintained its BMD advantage.

These gains are not merely numerical. A meta-analysis published in the Journal of Bone and Mineral Research estimated that each 1% increase in hip BMD corresponds to an approximately 5% reduction in hip fracture risk [11]. By this metric, the 3.4 percentage-point advantage romosozumab holds over alendronate at the total hip at 12 months translates to a meaningful clinical difference.

Alendronate's BMD trajectory is slower but sustained. Long-term extension data from the FLEX trial showed that 10 years of continuous alendronate therapy produced cumulative BMD gains of 13.7% at the lumbar spine and 6.7% at the total hip [12]. Romosozumab achieves a similar magnitude of lumbar spine gain in one-tenth the time.

Safety and the Cardiovascular Signal

Efficacy does not exist in a vacuum. The FDA approved romosozumab in April 2019 but attached a boxed warning about potential cardiovascular risk, based on a numerical imbalance observed in the ARCH trial [13].

During the first 12 months of ARCH, adjudicated major adverse cardiovascular events (MACE) occurred in 2.5% of romosozumab-treated patients versus 1.9% of alendronate-treated patients [5]. This difference was not statistically significant, but it was enough to prompt the boxed warning. Romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year [13].

By comparison, alendronate carries no cardiovascular warning. Its long-term safety profile, built over three decades of use, includes rare but recognized risks: osteonecrosis of the jaw (ONJ) at an estimated incidence of 1 in 10,000 to 1 in 100,000 patient-years of oral bisphosphonate exposure, and atypical femoral fractures (AFF) with prolonged use beyond 5 years [14]. The AACE 2020 clinical practice guidelines recommend reassessing bisphosphonate therapy after 5 years of oral use to weigh ongoing benefit against these uncommon risks [15].

Romosozumab's 12-month treatment limit means its long-term skeletal risks are inherently constrained. No cases of ONJ or AFF were attributed to romosozumab in clinical trials [5, 10]. Injection site reactions occurred in 5.2% of romosozumab patients in FRAME [10]. Hypocalcemia is possible with either drug, particularly in patients with vitamin D deficiency.

Who Should Get Which Drug First

The choice between starting with alendronate or romosozumab depends almost entirely on fracture risk severity, cardiovascular status, and access.

The 2020 AACE/ACE guidelines stratify patients into "high" and "very high" fracture risk categories [15]. Very high risk includes patients with a recent osteoporotic fracture (within the past 12 months), fractures while on approved osteoporosis therapy, multiple fractures, fractures while taking drugs that cause skeletal harm (e.g., long-term glucocorticoids), very low T-scores (below -3.0), high fall risk, or a FRAX 10-year probability of major osteoporotic fracture exceeding 30% or hip fracture exceeding 4.5% [15].

For very high-risk patients, AACE recommends anabolic therapy first, followed by transition to an antiresorptive [15]. This "build, then maintain" approach exploits the rapid BMD gains from agents like romosozumab or teriparatide, then locks those gains in place with a bisphosphonate such as alendronate.

For patients at high (but not very high) fracture risk, alendronate remains appropriate first-line therapy. Its proven efficacy, oral convenience, generic pricing, and extensive safety record make it a rational starting point. If a patient on alendronate sustains a fracture or shows continued BMD decline, escalation to romosozumab should be considered [15].

Cardiovascular history is the critical gatekeeper for romosozumab. In any patient with recent MI or stroke, romosozumab is off the table regardless of fracture risk [13].

Sequencing: Why Order Matters

Stopping romosozumab without starting a follow-on antiresorptive leads to rapid BMD loss. This is not a theoretical concern. Extension data from FRAME showed that BMD gains from romosozumab declined substantially within 12 months of discontinuation when no antiresorptive was introduced [10].

The ARCH trial was designed with this pharmacology in mind: every patient in the romosozumab arm transitioned to alendronate after 12 months. The romosozumab-to-alendronate sequence preserved and, in some cases, extended the BMD gains achieved during the anabolic phase [5].

The reverse sequence (alendronate first, then romosozumab) is less well-studied but pharmacologically sound. Patients who have been on a bisphosphonate may have a blunted anabolic response to romosozumab due to residual antiresorptive effects in the bone microenvironment [16]. A study published in the Journal of Bone and Mineral Research found that prior alendronate use attenuated, but did not eliminate, the BMD response to romosozumab [16]. Lumbar spine BMD still increased by 9.0% over 12 months in patients switching from alendronate to romosozumab, compared to 13.7% in treatment-naive patients [5, 16].

This blunting effect is one reason guidelines favor the anabolic-first approach for patients who qualify. Starting with romosozumab captures the full magnitude of the anabolic window, then transitions to alendronate when the window naturally closes at 12 months.

Cost, Access, and Real-World Prescribing

Clinical trial efficacy and real-world use often diverge, and the alendronate-versus-romosozumab decision is a clear example. Generic alendronate 70 mg weekly tablets cost between $4 and $12 per month at most U.S. pharmacies [8]. Romosozumab carries a wholesale acquisition cost of approximately $1,825 per monthly dose, or roughly $22,500 for the full 12-month course [8].

Insurance coverage for romosozumab varies. Medicare Part B covers it as a physician-administered injectable, but prior authorization requirements are common. Many commercial insurers require documentation of a T-score at or below -2.5 with a prior fragility fracture, or failure of at least one prior osteoporosis therapy, before approving romosozumab [8].

The cost differential has practical implications for population health. A 2021 cost-effectiveness analysis published in Osteoporosis International estimated that romosozumab followed by alendronate was cost-effective compared to alendronate alone only in patients with a 10-year hip fracture probability exceeding 7.5%, approximately twice the AACE threshold for "very high risk" [17]. For patients closer to the treatment threshold, alendronate monotherapy delivered comparable value per quality-adjusted life-year.

Adherence patterns also differ. Oral bisphosphonate adherence is notoriously poor: roughly 50% of patients discontinue alendronate within the first year, often due to gastrointestinal side effects or the burden of fasting requirements [18]. Romosozumab, administered as a monthly in-office injection, may avoid these adherence barriers, though its 12-month time-limited course means adherence is less of a long-term concern.